[go: up one dir, main page]

EP0708658A4 - VACCINE CONTAINING A RECOMBINANT CYTOMEGALOVIRUS - Google Patents

VACCINE CONTAINING A RECOMBINANT CYTOMEGALOVIRUS

Info

Publication number
EP0708658A4
EP0708658A4 EP94915386A EP94915386A EP0708658A4 EP 0708658 A4 EP0708658 A4 EP 0708658A4 EP 94915386 A EP94915386 A EP 94915386A EP 94915386 A EP94915386 A EP 94915386A EP 0708658 A4 EP0708658 A4 EP 0708658A4
Authority
EP
European Patent Office
Prior art keywords
vaccine containing
recombinant cytomegalovirus
cytomegalovirus
recombinant
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94915386A
Other languages
German (de)
French (fr)
Other versions
EP0708658A1 (en
Inventor
Stanley A Plotkin
Robert P Ricciardi
Eva Gonczol
Klara Berencsi
Robert F Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
US Department of Health and Human Services
Original Assignee
Wistar Institute of Anatomy and Biology
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology, US Department of Health and Human Services filed Critical Wistar Institute of Anatomy and Biology
Publication of EP0708658A1 publication Critical patent/EP0708658A1/en
Publication of EP0708658A4 publication Critical patent/EP0708658A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP94915386A 1993-04-16 1994-04-15 VACCINE CONTAINING A RECOMBINANT CYTOMEGALOVIRUS Withdrawn EP0708658A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4897893A 1993-04-16 1993-04-16
US48978 1993-04-16
PCT/US1994/004180 WO1994023744A1 (en) 1993-04-16 1994-04-15 Recombinant cytomegalovirus vaccine

Publications (2)

Publication Number Publication Date
EP0708658A1 EP0708658A1 (en) 1996-05-01
EP0708658A4 true EP0708658A4 (en) 1997-05-21

Family

ID=21957451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94915386A Withdrawn EP0708658A4 (en) 1993-04-16 1994-04-15 VACCINE CONTAINING A RECOMBINANT CYTOMEGALOVIRUS

Country Status (3)

Country Link
EP (1) EP0708658A4 (en)
CA (1) CA2160583A1 (en)
WO (1) WO1994023744A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
WO1997040165A1 (en) 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
US6086876A (en) * 1997-02-07 2000-07-11 The Wistar Insitute Methods and compositions for the inhibition of interleukin-12 production
AU4323599A (en) 1998-05-29 1999-12-13 Instituto Superiore Di Sanita Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
KR20090036151A (en) 2000-07-19 2009-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 Novel fibroblast growth factor (FFF23) and methods of use thereof
EP1404713A4 (en) 2001-05-24 2004-09-22 Human Dna Technology Inc Novel keratinocyte growth factor-2 analogue in hair follicle
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
AU2003262886A1 (en) 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7608433B2 (en) 2005-02-09 2009-10-27 Idexx Laboratories Method of detection of classical swine fever
MX336958B (en) 2005-11-15 2016-02-05 Philadelphia Children Hospital METHODS AND COMPOSITIONS TO MODULATE HEMOSTASIA.
DK1969003T3 (en) 2005-12-14 2010-12-13 Hermo Pharma Ltd Applications of a neurotrophic factor protein
WO2007101106A2 (en) 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis using variant forms of activated factor v
KR20090098880A (en) 2006-12-12 2009-09-17 바이오렉시스 파마슈티칼 코포레이션 Transferrin Fusion Protein Library
FI20070808A0 (en) 2007-10-25 2007-10-25 Mart Saarma Split variants of GDNF and uses thereof
FI20080326A0 (en) 2008-04-30 2008-04-30 Licentia Oy Neurotrophic factor MANF and its uses
JP2012509670A (en) 2008-11-21 2012-04-26 ザ チルドレンズ ホスピタル オブ フィラデルフィア Snake fifth factor as a blood coagulation promoter and method of use
CA2820706C (en) 2010-12-03 2018-05-22 Ms Technologies, Llc Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
WO2013049804A1 (en) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
US9783817B2 (en) 2013-03-04 2017-10-10 Arkansas State University Methods of expressing and detecting activity of expansin in plant cells
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
PE20231949A1 (en) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS
AU2018281306B2 (en) 2017-06-07 2025-04-17 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
HRP20250766T1 (en) 2020-10-15 2025-08-15 F. Hoffmann - La Roche Ag NUCLEIC ACID CONSTRUCTS FOR VA RNA TRANSCRIPTION
US20220154223A1 (en) 2020-10-15 2022-05-19 Hoffmann-La Roche Inc. Nucleic acid constructs for simultaneous gene activation
JP2025516117A (en) 2022-04-13 2025-05-27 エフ． ホフマン－ラ ロシュ アーゲー Methods for determining the AAV genome
EP4529614A1 (en) 2022-05-23 2025-04-02 F. Hoffmann-La Roche AG Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
AU2023305838A1 (en) 2022-07-14 2024-11-28 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
CN119816351A (en) 2022-09-12 2025-04-11 豪夫迈·罗氏有限公司 Method for separating intact AAV particles from empty AAV particles
KR20250141727A (en) 2023-02-07 2025-09-29 에프. 호프만-라 로슈 아게 Anti-AAV particle antibody detection method
WO2024194280A1 (en) 2023-03-21 2024-09-26 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
US20260022401A1 (en) 2024-07-22 2026-01-22 Hoffmann-La Roche Inc. Novel AAV rep ORFs and Rep polypeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000062A1 (en) * 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (en) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
EP0389286A2 (en) * 1989-03-24 1990-09-26 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1990011302A1 (en) * 1989-03-24 1990-10-04 University Of Iowa Research Foundation Antibody and t cell recognition sites on glycoproteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000062A1 (en) * 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (en) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
EP0389286A2 (en) * 1989-03-24 1990-09-26 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1990011302A1 (en) * 1989-03-24 1990-10-04 University Of Iowa Research Foundation Antibody and t cell recognition sites on glycoproteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERENCSI ET AL: "HUMAN CYTOMEGALOVIRUS (HCMV) GLYCOPROTEIN-B (GB)-SPECIFIC CELL-MEDIATED IMMUNITY IN EXPERIMENTAL ANIMALS", ACTA MICROBIOLOGICA HUNGARICA, vol. 38, 1991, pages 170 - 171, XP000645013 *
BERENCSI ET AL: "MURINE CYTOTOXIC T CELL RESPONSE SPECIFIC FOR HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B (GB) INDUCED BY ADENOVIRUS AND VACCINIA VIRUS RECOMBINANTS EXPRESSING GB", JOURNAL OF GENERAL VIROLOGY, vol. 74, November 1993 (1993-11-01), pages 2507 - 2512, XP002026070 *
LIU ET AL: "THE N-TERIMINAL 513 AMINO ACIDS OF THE ENVELOPE GLYCOPROTEIN GB OF HUMAN CYTOMEGALOVIRUS STIMLATES BOTH B- AND T-CELL IMMUNE RESPONSES IN HUMANS", JOURNAL OF VIROLOGY, vol. 65, no. 3, March 1991 (1991-03-01), pages 1644 - 1648, XP000645036 *
See also references of WO9423744A1 *

Also Published As

Publication number Publication date
CA2160583A1 (en) 1994-10-27
EP0708658A1 (en) 1996-05-01
WO1994023744A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
EP0708658A4 (en) VACCINE CONTAINING A RECOMBINANT CYTOMEGALOVIRUS
DK0761231T3 (en) Vaccine containing adjuvants
FI955667L (en) Adjuvants for RSV vaccines
ATE151627T1 (en) SUCTION BOTTLE
FI945811A7 (en) Des-Tyr-dynorphin analogs
FI944052A0 (en) Oral vaccine
PL307402A1 (en) Vaccine containing a hepatitis a virus
NO952336D0 (en) Insulin analogues
IL101639A0 (en) Recombinant influenza vaccines
FI943418A7 (en) Synthetic peptides for rubella vaccine
FI930022A0 (en) CHEMIST FOERFARANDE
FI944428A7 (en) Antiviral peptides
FI924395A7 (en) Neither A nor B peptides
GB9321345D0 (en) Instant nail mask
DK136492D0 (en) A PHARMACEUTICAL FORMULATION
ITMI922675A1 (en) IMMUNOGENIC PEPTIDES
NO943251D0 (en) Oral vaccine
GB9323820D0 (en) Vaccine
SE9203057D0 (en) NEW VACCINE AGAINST SCHISTOSOMIASIS
GB9206786D0 (en) Vaccine
GB9213308D0 (en) Vaccine
GB9222156D0 (en) Vaccine
GB9206797D0 (en) Vaccine
GB9206788D0 (en) Vaccine
SE9201313D0 (en) RECOMBINANT VACCINE VECTOR

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/00

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990316

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030730